Founded in 1972, Solabia develops and manufactures molecules and active ingredients for the cosmetic, pharmaceutical and nutraceutical industries, peptones and protein hydrolysates for bio-industries and microbiological diagnostics for agro-food, cosmetic, pharmaceutical and environmental laboratories.

Having invested in the Cosmetics, Pharmaceutical, Nutritional, Diagnostics and Biotechnology sectors, Solabia possesses of a coherent ensemble of complementary know-how in biotechnology, fine chemicals, plant extraction and microbiology.

Regenics collaborates with Solabia Group on encapsulation bioactive ingredient-LEX® and deliver it to cosmetic industry.

Solabias’ research is state-of-the-art in areas of in vitro skin models, methods for assessing gene and protein expression in skin cells, skin wound healing assays, as well as live imaging to measure cell movement over time. We have a number of in vitro and in vivo assays, we utilize multiple cell lines, skin cell models as well as tissue-models. Regenics have also developed novel methods for efficacy studies, and exerts a number of downstream applications on gene and protein level.

Current research focus
Regenics’ primary research focus is to develop, scientifically document, and patent a multifunctional cosmetic ingredient, LEX™, and products for wound healing.

Contact information:

 

Address:
29, rue Delizy
93698 Pantin Cedex
France

Website: www.solabia.com

Regenics' contact person:
Vincent BLAIN
Export Manager
e-mail:  vincent.blain@solabia.fr

Regenics AS has developed a number of assays and techniques to study effects of various substances on skin cells both in vitroin vivo and in the clinic. Our focus is to develop products and techniques for therapeutic skin applications and to improve skin appearance.